Dare Bioscience’s (DARE) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Dare Bioscience (NASDAQ:DARE) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $12.00 target price on the biotechnology company’s stock.

A number of other analysts have also commented on the company. Maxim Group raised Dare Bioscience from a “hold” rating to a “buy” rating and set a $8.00 target price for the company in a research report on Thursday, September 4th. Wall Street Zen raised Dare Bioscience to a “hold” rating in a research note on Saturday, August 16th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Dare Bioscience in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dare Bioscience has an average rating of “Hold” and an average target price of $10.00.

Dare Bioscience Stock Performance

NASDAQ:DARE opened at $1.72 on Tuesday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.06. Dare Bioscience has a twelve month low of $1.61 and a twelve month high of $9.19. The company has a fifty day moving average of $1.97 and a 200-day moving average of $2.30. The firm has a market capitalization of $24.58 million, a P/E ratio of -0.92 and a beta of 0.77.

Dare Bioscience (NASDAQ:DARE) last posted its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05. The company had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.01 million. As a group, sell-side analysts anticipate that Dare Bioscience will post -0.49 EPS for the current year.

Hedge Funds Weigh In On Dare Bioscience

A number of hedge funds have recently bought and sold shares of the company. Raymond James Financial Inc. raised its holdings in shares of Dare Bioscience by 810.6% in the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 13,650 shares during the last quarter. Virtu Financial LLC bought a new stake in Dare Bioscience in the 3rd quarter worth about $37,000. Finally, AMH Equity Ltd grew its position in Dare Bioscience by 17.8% in the 2nd quarter. AMH Equity Ltd now owns 193,603 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 29,301 shares in the last quarter. 6.70% of the stock is owned by hedge funds and other institutional investors.

About Dare Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.